Literature DB >> 20943782

Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD.

James B Wetmore1, Peter W Santos, Jonathan D Mahnken, Ron Krebill, Rochelle Menard, Hema Gutta, L Darryl Quarles.   

Abstract

CONTEXT: The positive association of elevated fibroblast growth factor-23 (FGF23) with PTH levels in the setting of secondary hyperparathyroidism is paradoxical to the purported effects of FGF23 to suppress PTH secretion.
OBJECTIVE: We used dynamic calcium-mediated suppression of PTH levels in hemodialysis (HD) patients to determine the relationship between FGF23 levels and parathyroid gland function.
DESIGN: HD patients with elevated PTH were washed out of vitamin D analogs and/or calcimimetics and then exposed them to a high-calcium dialysate bath designed to suppress PTH.
SETTING: The study was conducted at an outpatient HD unit of an academic medical center. PARTICIPANTS: Eighteen maintenance HD patients with elevated PTH levels participated in the study. MAIN OUTCOME MEASURES: Ionized calcium (iCa), PTH, and FGF23 levels were measured during HD. The slope of the relationship between iCa and PTH (a marker of parathyroid gland mass) and the iCa level required for a 50% reduction in PTH were determined, and the association of these with FGF23 levels was determined.
RESULTS: Increased baseline log FGF23 levels were associated with putative alterations in gland mass as estimated by significantly shallower slopes of the iCa/PTH suppression curves (P = 0.0004), but there was no association between FGF23 and calcium sensing as measured by ionized Ca associated with a 50% suppression of PTH (P = 0.38). FGF23 levels decreased significantly during HD, but this change was not correlated with decrements in either renal phosphate or PTH.
CONCLUSIONS: High FGF23 levels may be a marker for parathyroid gland hyperplasia in HD patients. Acute reductions in neither PTH nor renal phosphate during dialysis correlated with PTH suppression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20943782      PMCID: PMC3038477          DOI: 10.1210/jc.2010-1277

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  28 in total

1.  FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.

Authors:  Takashi Shimada; Hisashi Hasegawa; Yuji Yamazaki; Takanori Muto; Rieko Hino; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  J Bone Miner Res       Date:  2003-12-29       Impact factor: 6.741

2.  Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo.

Authors:  E G Nabel; Z Y Yang; G Plautz; R Forough; X Zhan; C C Haudenschild; T Maciag; G J Nabel
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

3.  Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production.

Authors:  Hitoshi Saito; Kenichiro Kusano; Masahiko Kinosaki; Hirotaka Ito; Michinori Hirata; Hiroko Segawa; Ken-Ichi Miyamoto; Naoshi Fukushima
Journal:  J Biol Chem       Date:  2002-11-04       Impact factor: 5.157

4.  FGF23 fails to inhibit uremic parathyroid glands.

Authors:  Rocío Canalejo; Antonio Canalejo; Julio Manuel Martinez-Moreno; M Encarnacion Rodriguez-Ortiz; Jose C Estepa; Francisco Javier Mendoza; Juan Rafael Munoz-Castaneda; Victoria Shalhoub; Yolanda Almaden; Mariano Rodriguez
Journal:  J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 10.121

5.  Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism.

Authors:  O S Indridason; H Heath; S Khosla; D A Yohay; L D Quarles
Journal:  Kidney Int       Date:  1996-11       Impact factor: 10.612

6.  Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain.

Authors:  T Yamashita; M Yoshioka; N Itoh
Journal:  Biochem Biophys Res Commun       Date:  2000-10-22       Impact factor: 3.575

7.  FGF-23 in patients with end-stage renal disease on hemodialysis.

Authors:  Yasuo Imanishi; Masaaki Inaba; Kiyoshi Nakatsuka; Kyoko Nagasue; Senji Okuno; Asami Yoshihara; Masakazu Miura; Akimitsu Miyauchi; Keisuke Kobayashi; Takami Miki; Tetsuo Shoji; Eiji Ishimura; Yoshiki Nishizawa
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

8.  Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.

Authors:  Tetsuhiko Sato; Yoshihiro Tominaga; Tsuneo Ueki; Norihiko Goto; Susumu Matsuoka; Akio Katayama; Toshihito Haba; Kazuharu Uchida; Shohei Nakanishi; Junichiro James Kazama; Fumitake Gejyo; Takeyoshi Yamashita; Masafumi Fukagawa
Journal:  Am J Kidney Dis       Date:  2004-09       Impact factor: 8.860

9.  Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.

Authors:  Shiguang Liu; Rong Guo; Leigh G Simpson; Zhou-Sheng Xiao; Charles E Burnham; L Darryl Quarles
Journal:  J Biol Chem       Date:  2003-07-21       Impact factor: 5.157

10.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Authors:  Mara Riminucci; Michael T Collins; Neal S Fedarko; Natasha Cherman; Alessandro Corsi; Kenneth E White; Steven Waguespack; Anurag Gupta; Tamara Hannon; Michael J Econs; Paolo Bianco; Pamela Gehron Robey
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

View more
  11 in total

Review 1.  The rachitic tooth.

Authors:  Brian L Foster; Francisco H Nociti; Martha J Somerman
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

2.  Lack of FGF23 response to acute changes in serum calcium and PTH in humans.

Authors:  Katherine Wesseling-Perry; Hejing Wang; Robert Elashoff; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2014-07-25       Impact factor: 5.958

Review 3.  Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.

Authors:  L Darryl Quarles
Journal:  Exp Cell Res       Date:  2012-03-07       Impact factor: 3.905

Review 4.  The role of FGF23 in CKD--with or without Klotho.

Authors:  Hirotaka Komaba; Masafumi Fukagawa
Journal:  Nat Rev Nephrol       Date:  2012-06-19       Impact factor: 28.314

5.  Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism.

Authors:  Tomasz Hryszko; Szymon Brzosko; Alicja Rydzewska-Rosolowska; Ewa Koc-Zorawska; Michal Mysliwiec
Journal:  Int Urol Nephrol       Date:  2011-08-27       Impact factor: 2.370

6.  S-nitrosoglutathione reductase-dependent PPARγ denitrosylation participates in MSC-derived adipogenesis and osteogenesis.

Authors:  Yenong Cao; Samirah A Gomes; Erika B Rangel; Ellena C Paulino; Tatiana L Fonseca; Jinliang Li; Marilia B Teixeira; Cecilia H Gouveia; Antonio C Bianco; Michael S Kapiloff; Wayne Balkan; Joshua M Hare
Journal:  J Clin Invest       Date:  2015-03-23       Impact factor: 14.808

7.  Beneficial effects of preemptive kidney transplantation on calcium and phosphorus disorders in early post-transplant recipients.

Authors:  Makoto Tsujita; Daijo Inaguma; Norihiko Goto; Takayuki Yamamoto; Takahisa Hiramitsu; Akio Katayama; Asami Takeda; Takaaki Kobayashi; Kunio Morozumi; Kazuharu Uchida; Shunji Narumi; Yoshihiko Watarai; Yoshihiro Tominaga
Journal:  Clin Exp Nephrol       Date:  2014-04-06       Impact factor: 2.801

8.  A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.

Authors:  Adrian Covic; Jutta Passlick-Deetjen; Miroslaw Kroczak; Beatrix Büschges-Seraphin; Adrian Ghenu; Pedro Ponce; Barbara Marzell; Angel L M de Francisco
Journal:  Nephrol Dial Transplant       Date:  2013-06-19       Impact factor: 5.992

9.  Effects of high doses of cholecalciferol in normal subjects: a randomized double-blinded, placebo-controlled trial.

Authors:  Birgitte Nygaard; Niels Erik Frandsen; Lisbet Brandi; Knud Rasmussen; Ove Vyff Oestergaard; Lars Oedum; Hans Christian Hoeck; Ditte Hansen
Journal:  PLoS One       Date:  2014-08-28       Impact factor: 3.240

10.  Phosphate control in reducing FGF23 levels in hemodialysis patients.

Authors:  Cristian Rodelo-Haad; Maria E Rodríguez-Ortiz; Alejandro Martin-Malo; M Victoria Pendon-Ruiz de Mier; M Luisa Agüera; Juan R Muñoz-Castañeda; Sagrario Soriano; Francisco Caravaca; M Antonia Alvarez-Lara; Arnold Felsenfeld; Pedro Aljama; Mariano Rodriguez
Journal:  PLoS One       Date:  2018-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.